<DOC>
	<DOC>NCT02837003</DOC>
	<brief_summary>To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES). Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.</brief_summary>
	<brief_title>3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients with coronary artery lesion who received percutaneous coronary intervention using Ultimaster sirolimuseluting stent. Patients considered appropriate to discontinue dual antiplatelet therapy at 3 months after stent implantation. Patients who have provided written informed consent. Patients previously experienced stent thrombosis. Patients who are unable to clinical followup procedure specified in the protocal for the present study. Patients who are enrolled or planned to participate in another clinical trials of antiplatelet therapy.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug-Eluting Stent</keyword>
</DOC>